The risk of developing cardiovascular disease in bipolar disorder. Biological factors and therapy

Cover Page

Cite item

Full Text

Abstract

Background. Bipolar disorder (BD) is one of the most common mental disorders characterized by alternating episodes of mania/hypomania and depression, as well as the possibility of developing mixed conditions. Correct and timely diagnosis of BD is important due to the presence of a high suicidal risk and a high predisposition to the development of cardiovascular disease (CVD). The risk of CVD is higher in ВD than in other mental disorders.

Materials and methods. A sample assessment was made of current studies focusing on the vascular-bipolar link. The search was carried out in the PubMed and eLIBRARY databases for the following keywords: bipolar disorder, psychopharmacology, cardiovascular disease, biological mediators.

Results. There are several biological factors which explain the close association and common pathogenetic mechanisms of BD and CVD. The most interesting of them are inflammation, oxidative stress, and brain-derived neurotrophic factor. Neuroimaging methods have shown similar structural brain changes in people with BD and with CVD. There is some evidence of the efficacy of statins and angiotensin-converting enzyme inhibitors in reducing cardio-vascular risk factors in BD patients.

Conclusion. The predisposition of patients of BD to CVD is beyond doubt. It is necessary to consider the peculiarities of the course of BD and conduct active monitoring and preventive measures to reduce the risk of developing life-threatening CVDs. Further research focused on the pathogenetic relationship between BD and CVD could provide more insight into this area.

About the authors

Sergey N. Mosolov

Moscow Research Institute of Psychiatry – a branch of the Serbsky National Medical Research Center for Psychiatry and Narcology; Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: profmosolov@mail.ru
ORCID iD: 0000-0002-5749-3964
SPIN-code: 3009-9162

д-р мед. наук, проф., рук. отд. терапии психических заболеваний Московского НИИ психиатрии, зав. каф. психиатрии, председатель Правления Московского отд-ния Российского общества психиатров, президент Российского общества биологической психиатрии

Russian Federation, Moscow; Moscow

Elizaveta Yu. Fedorova

Moscow Research Institute of Psychiatry – a branch of the Serbsky National Medical Research Center for Psychiatry and Narcology

Email: lizzyfedorova@gmail.com
ORCID iD: 0000-0002-4759-5043
SPIN-code: 4474-9460

мл. науч. сотр. отд. терапии психических расстройств Московского НИИ психиатрии

Russian Federation, Moscow

References

  1. Психиатрия: национальное руководство. Краткое издание. Под ред. Т.Б. Дмитриевой, Н.Г. Незнанова, Ю.А. Александровского и др. М.: ГЕОТАР Медицина, 2012 [Psikhiatriia: natsional'noe rukovodstvo. Kratkoe izdanie. Pod red. TB Dmitrievoi, NG Neznanova, UA Aleksandrovskogo. Moscow, Geotar Medicina. 2012 (in Russian)].
  2. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994;31(4):281-94. doi: 10.1016/0165-0327(94)90104-X
  3. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-74.
  4. Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: The BRIDGE study. Arch Gen Psychiatry. 2011. 68(8):791-8. doi: 10.1001/archgenpsychiatry.2011.87
  5. Mosolov S, Ushkalova A, Kostyukova E, et al. Bipolar II disorder in patients with a current diagnosis of recurrent depression. Bipolar Disord. 2014;16(4):389-99. doi: 10.1111/bdi.12192
  6. Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88:217-33. doi: 10.1016/j.jad.2005.05.0111.
  7. Solomon DA, Leon AC, Maser JD, et al. Distinguishing bipolar major depression from unipolar major depression with the screening assess-ment of depression-polarity (SAD-P). J Clin Psychiatry. 2006;67(3):434-42. doi: 10.4088/JCP.v67n0315
  8. Mosolov SN, Ushkalova AV, Kostyukova EG, et al. Validation of the Russian version of the hypomania checklist (HCL-32) for the detection of bipolar II disorder in patients with a current diagnosis of recurrent depression. J Affect Disord. 2014;155(1):90-5. doi: 10.1016/j.jad.2013.10.029
  9. Osby U, Westman J, Hallgren J, et al. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010. Eur J Public Health. 2016;26:867-71. doi: 10.1093/eurpub/ckv245
  10. Goldstein BI, Fagiolini A, Houck P, et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11:657-62. doi: 10.1111/j.1399-5618.2009.00735.x
  11. Мосолов С.Н., Федорова Е.Ю. Риск развития сердечно-сосудистых заболеваний при биполярном расстройстве. Клинико-социальные факторы. Терапевтический архив. 2021;93(12):1556-61 [Mosolov SN, Fedorova EYu. The risk of developing cardiovascular disease in bipolar disorder. Clinical and social factors. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1556-61 (in Russian)]. doi: 10.26442/00403660.2021.12.201175
  12. Петрова Н.Н., Майорова М.А. Роль кинуренинового пути в развитии и терапии депрессии. Современная терапия психических расстройств. 2018;4:2-7 [Petrova NN, Maiorova MA. The Role of Kynurenine Pathway in Development and Therapy of Depression. Current Therapy of Mental Disorders. 2018;4:2-7 (in Russian)]. doi: 10.21265/PSYPH.2018.47.21771
  13. Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep. 2013;15:425. doi: 10.1007/s11920-013-0425-9
  14. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116:214-7. doi: 10.1016/j.jad.2008.12.001
  15. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16-27. doi: 10.1016/j.jad.2012.06.010
  16. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-95. doi: 10.7326/0003-4819-151-7-200910060-00009
  17. Kattoor AJ, Pothineni NVK, Palagiri D, et al. Oxidative Stress in Atherosclerosis. Curr Atheroscler Rep. 2017;19:42. doi: 10.1007/s11883-017-0678-6
  18. Forstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ Res. 2017;120:713-35. doi: 10.1161/CIRCRESAHA.116.309326
  19. Incalza MA, D'Oria R, Natalicchio A, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1-19. doi: 10.1016/j.vph.2017.05.005
  20. Huggins GS. Genetic Susceptibility to Oxidative Stress and Cardiovascular Disease. EBioMedicine. 2015;2:1864-5. doi: 10.1016/j.ebiom.2015.11.042
  21. Andreazza AC, Shao L, Wang J-F, et al. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder mitochondrial dysfunction and oxidative stress. Arch Gen Psychiatry. 2010;67:360-8. doi: 10.1001/archgenpsychiatry.2010.22
  22. Wang J-F, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009;11:523-9. doi: 10.1111/j.1399-5618.2009.00717.x
  23. Jin H, Chen Y, Wang B, et al. Association between brain-derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease. BMC Cardiovasc Disord. 2018;18:23. doi: 10.1186/s12872-018-0762-z
  24. Kaess BM, Preis SR, Lieb W, et al. Circulating Brain-derived Neurotrophic Factor Concentrations and the Risk of Cardiovascular Disease in the Community. J Am Heart Assoc. 2015;4:e001544. doi: 10.1161/JAHA.114.001544
  25. Alomari MA, Khabour OF, Maikano A, et al. Vascular function and brain-derived neurotrophic factor: The functional capacity factor. Vasc Med. 2015;20:518-26. doi: 10.1177/1358863X15598390
  26. Donovan MJ, Lin MI, Wiegn P, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development. 2000;127:4531-40. doi: 10.1242/dev.127.21.4531
  27. Matsuo K, Walss-Bass C, Nery FG, et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology. 2009;34:1904-13. doi: 10.1038/npp.2009.23
  28. Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995-1004. doi: 10.1016/j.jpsychires.2011.03.002
  29. Smith EE. Leukoaraiosis and stroke. Stroke. 2010;41:S139-43. doi: 10.1161/STROKEAHA.110.596056
  30. Beyer JL, Young R, Kuchibhatla M, et al. Hyperintense MRI lesions in bipolar disorder: A meta-analysis and review. Int Rev Psychiatry. 2009;21:394-409. doi: 10.1080/09540260902962198
  31. Bond DJ, Ha TH, Lang DJ, et al. Body mass index-related regional gray and white matter volume reductions in first-episode mania patients. Biol Psychiatry. 2014;76:138-45. doi: 10.1016/j.biopsych.2013.08.030
  32. Kuswanto CN, Sum MY, Yang GL, et al. Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. Psychol Med. 2014;44:533-41. doi: 10.1017/S0033291713000858
  33. Bond DJ, Su W, Honer WG, et al. Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study. Bipolar Disord. 2019;21:50-60. doi: 10.1111/bdi.12722
  34. Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016;36:1653-67. doi: 10.1177/0271678X16662891
  35. Toma S, MacIntosh BJ, Swardfager W, et al. Cerebral blood flow in bipolar disorder: A systematic review. J Affect Disord. 2018;241:505-13. doi: 10.1016/j.jad.2018.08.040
  36. Bhardwaj R, Chakrabarti S, Mittal BR, et al. A single photon emission computerized tomography (SPECT) study of regional cerebral blood flow in bipolar disorder. World J Biol Psychiatry. 2010;11:334-43. doi: 10.3109/15622970802575977
  37. Zhao L, Wang Y, Jia Y, et al. Microstructural Abnormalities of Basal Ganglia and Thalamus in Bipolar and Unipolar Disorders: A Diffusion Kurtosis and Perfusion Imaging Study. Psychiatry Investig. 2017;14:471-82. doi: 10.4306/pi.2017.14.4.471
  38. Kruger S, Alda M, Young LT, et al. Risk and resilience markers in bipolar disorder: brain response to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry. 2006;163:257-64. doi: 10.1176/appi.ajp.163.2.257
  39. Almeida JR, Mourao-Miranda J, Aizenstein HJ, et al. Pattern recognition analysis of anterior cingulate cortex blood flow to classify depression polarity. Br J Psychiatry. 2013;203:310-1. doi: 10.1192/bjp.bp.112.122838
  40. Kim SW, Kang HJ, Bae KY, et al. Interactions between proinflammatory cytokines and statins on depression in patients with acute coronary syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80:250-4. doi: 10.1016/j.pnpbp.2017.07.003
  41. Persons JE, Robinson JG, Payne ME, et al. Serum lipid changes following the onset of depressive symptoms in postmenopausal women. Psychiatry Res. 2017;247:282-7. doi: 10.1016/j.psychres.2016.12.006
  42. Salagre E, Fernandes BS, Dodd S, et al. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235-42. doi: 10.1016/j.jad.2016.04.047
  43. O'Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med. 2012;10:154. doi: 10.1186/1741-7015-10-154
  44. Cipriani A, Saunders K, Attenburrow MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21:1324-32. doi: 10.1038/mp.2016.86
  45. Brownstein DJ, Salagre E, Kohler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018;52:24-38. doi: 10.1177/0004867417721654
  46. Boal AH, Smith DJ, McCallum L, et al. Monotherapy with Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. Hypertension. 2016;68:1132-8. doi: 10.1161/HYPERTENSIONAHA.116.08188
  47. Мосолов С.Н. Сравнительная эффективность профилактического применения карбоната лития, карбамазепина, вальпроата натрия при аффективных и шизоаффективных психозах. Журнал неврологии и психиатрии им. С.С. Корсакова. 1991;4:78-83 [Mosolov SN. Comparative efficacy of preventive use of lithium carbonate, carbamazepine and sodium valproate in affective and schizoaffective psychoses. S.S. Korsakov Journal of Neurology and Psychiatry. 1991;4:78-83 (in Russian)].
  48. Petri E, Bacci O, Barbuti M, et al. Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the BRIDGE-II-MIX study. Bipolar Disord. 2017;378(12):1561-8. doi: 10.1111/bdi.12519
  49. Bowden CL, Hranov L, Chen E, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol. 2010;25:60-7. doi: 10.1097/YIC.0b013e328333ac1b
  50. Алфимов П.В., Рывкин П.В., Ладыженский М.Я., и др. Метаболический синдром у больных шизофренией (обзор литературы). Современная терапия психических расстройств. 2014;3:8-14 [Alfimov PV, Ryvkin PV, Ladyzhensky MY, et al. Metabolic syndrome in patients with schizophrenia (a review). Current Therapy of Mental Disorders. 2014;3:8-14 (in Russian)].
  51. Al-Amin MM, Nasir Uddin MM, Mahmud Reza H. Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin Psychopharmacol Neurosci. 2013;11:144-51. doi: 10.9758/CPN.2013.11.3.144
  52. Костюкова Е.Г. Алгоритм биологической терапии депрессии при биполярном аффективном расстройстве. Современная терапия психи- ческих расстройств. 2020;4:36-45 [Kostyukova EG. Algorithm of biological treatment of depression in bipolar affective disorder. Current Therapy of Mental Disorders. 2020;4:36-45 (in Russian)]. doi: 10.21265/PSYPH.2020.97.57.005

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies